NanoViricides, Inc. (NYSE American: NNVC) filed its Q1 2025 report and announced progress on NV-387, its broad-spectrum antiviral drug candidate. The company has received clearance from the DRC’s National Ethics Committee to submit a Phase II trial application for MPox and is also initiating programs targeting measles and avian flu. NV-387 previously completed Phase I with no adverse events and has shown superior activity in animal models compared to approved antivirals for COVID, influenza, RSV, and smallpox. Financially, NNVC reported $2.73 million in cash, $6.98 million in property and equipment, and $1.2 million in current liabilities, but indicated that additional funding is needed to support operations beyond early 2026.
To view the full press release, visit https://ibn.fm/VxmLu
About NanoViricides Inc.
NanoViricides is a development-stage company that is creating special purpose nanomaterials for antiviral therapy. The company’s novel nanoviricide(TM) class of drug candidates and the nanoviricide(TM) technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. NanoViricides’ lead drug candidate is NV-387, a broad-spectrum antiviral drug that the company plans to develop as a treatment of RSV, COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company is currently focused on advancing NV-387 into Phase II human clinical trials. NanoViricides’ other advanced candidate is NV-HHV-1 for the treatment of Shingles. The company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. NV-CoV-2 (“API NV-387”) is the company’s nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is NanoViricides’ other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. For more information about the company, visit www.NanoViricides.com.
NOTE TO INVESTORS: The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
